<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961101</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-019</org_study_id>
    <nct_id>NCT02961101</nct_id>
  </id_info>
  <brief_title>Anti-PD-1 Antibody in Combination With Low-dose Decitabine in Relapsed or Refractory Malignancies</brief_title>
  <official_title>Anti-PD-1 Antibody in Combination With Low-dose Decitabine in Relapsed or Refractory Malignancies: an Open-label Phase I/II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Han weidong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1
      antibody in combination with low-dose decitabine in patients with relapsed or refractory
      malignancies, including Non-Hodgkin'lymphoma, anti-PD-1-resistant Hodgkin'lymphoma,
      gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung
      cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: To assess the feasibility and safety for Anti-PD-1 antibody in combination
      with decitabine administered every 3 weeks to subjects with relapsed or refractory
      malignancies.

      Secondary objectives: 1) To assess the antitumor activity of Anti-PD-1 antibody in
      combination with decitabine in subjects with relapsed or refractory malignancies. 2) To
      characterize the immunological effects of Anti-PD-1 antibody in combination with decitabine.
      3) To characterize the immunological effects of Anti-PD-1 antibody in combination with
      decitabine.

      Exploratory objectives: 1) To analysis of potential biological parameters correlated to
      clinical response and toxicities. 2) To search predictive biomarkers to guide the choose of
      patients undergoing the treatment of Anti-PD-1 antibody in combination with decitabine.

      Safety Evaluation: Adverse events will be assessed continuously during the study and for 100
      days post last treatment,and will be evaluated according to the NCI CTCAE Version 4.0.

      Efficacy Evaluation: 1) Treatment response to lymphoma was defined using the International
      Workshop to Standardize Response Criteria for non-Hodgkin's Lymphomas; 2) Treatment response
      to solid tumors was defined using Response Evaluation Criteria in Solid Tumors (RECIST1.1).

      evaluation index: BOR; ORR; PFS and OS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response by Response Evaluation Criteria in Solid Tumors (RECIST1.1).</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response by the International Workshop to Standardize Response Criteria for lymphomas.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Malignancies Multiple</condition>
  <arm_group>
    <arm_group_label>Anti-PD-1 antibody+decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine was administrated at 10mg/d on day1 to 5, followed by Anti-PD-1 antibody 1-3mg/kg on day8 IV Q3 weeks until progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-PD-1 antibody</intervention_name>
    <description>Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks</description>
    <arm_group_label>Anti-PD-1 antibody+decitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks</description>
    <arm_group_label>Anti-PD-1 antibody+decitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have histological confirmation of relapsed or refractory
             malignancies,including Non-Hodgkin'lymphoma, anti-PD-1-resistant Hodgkin'lymphoma,
             gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or
             lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.

          2. 12 to 80 years of age.

          3. ECOG performance of less than 2.

          4. Life expectancy of at least 3 months.

          5. Subjects with lymphoma must have at least one measureable lesion &gt;1 cm as defined by
             lymphoma response criteria; with solid tumors must have at least one measureable
             lesion &gt;1 cm per RECIST1.1.

          6. Subjects must have received at least two prior chemotherapy regimen, and must be off
             therapy for at least 4 weeks prior to Day 1. Subjects with autologous hematopoietic
             stem-cell transplantation are eligible which must be more than 3 months.

          7. Subjects must have adequate bone marrow, live, renal, lung and heart functions.

               1. Absolute neutrophil count greater than or equal to 1,000/μL.

               2. Platelet count greater than or equal to 70,000/µL.

               3. Serum bilirubin level less than or equal to 1.5 x upper limits of normal (ULN).

               4. Serum creatinine less than or equal to 1.5 x ULN.

               5. Alanine aminotransferase [ALT or SGPT] and aspartate aminotransferase [AST or
                  SGOT] less than or equal to 2.5 x ULN.

        Exclusion Criteria:

          1. Subjects with any autoimmune disease or history of syndrome that requires
             corticosteroids or immunosuppressive medications.

          2. Serious uncontrolled medical disorders or active infections, pulmonary and intestinal
             infection especially.

          3. Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in 1
             month .

          4. Prior organ allograft.

          5. Women who are pregnant or breastfeeding.

          6. Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (eg, infectious disease) illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunmeng Wang, Master</last_name>
    <role>Study Director</role>
    <affiliation>Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wenying Zhang, Master</last_name>
    <role>Study Director</role>
    <affiliation>Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yang Liu, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meixia Chen, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yan Zhang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qian Mei, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jing Nie, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiang Li, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liang Dong, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lu Shi, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaichao Feng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jingdan Qiu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hejin Jia, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weidong Han, doctor</last_name>
    <phone>+86-010-66937463</phone>
    <email>hanwdrsw@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qingming Yang, doctor</last_name>
    <phone>+86-010-55499341</phone>
    <email>yangqm@medmail.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Biotherapeutic Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Han, Doctor</last_name>
      <phone>+86-10-66937463</phone>
      <email>hanwdrsw@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Qingming Yang, Doctor</last_name>
      <phone>+86-10-55499341</phone>
      <email>yangqm@medmail.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Yang Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chunmeng Wang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenying Zhang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meixia Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weidong Han, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingming Yang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qian Mei, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Nie, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan Zhang, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaichao Feng, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jingdan Qiu, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hejin Jia, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiang Li, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liang Dong, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lu Shi, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Mei Q, Chen M, Lu X, Li X, Duan F, Wang M, Luo G, Han W. An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma. Oncotarget. 2015 Jun 30;6(18):16698-711.</citation>
    <PMID>25895027</PMID>
  </results_reference>
  <results_reference>
    <citation>Nie J, Zhang Y, Li X, Chen M, Liu C, Han W. DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire. Oncotarget. 2016 Jun 21;7(25):37882-37892. doi: 10.18632/oncotarget.9352.</citation>
    <PMID>27191266</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>November 10, 2016</last_update_submitted>
  <last_update_submitted_qc>November 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>relapsed or refractory</keyword>
  <keyword>malignancies</keyword>
  <keyword>decitabine</keyword>
  <keyword>anti-PD-1 antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

